Skip to content

Differences in Treatment Characteristics and Patient and Therapist Satisfaction Between Robot Assisted Therapy and Conventional Occupational Therapy Among Individuals Post Stroke

Differences in Treatment Characteristics and Patient and Therapist Satisfaction Between Robot Assisted Therapy and Conventional Occupational Therapy Among Individuals Post Stroke

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07425158
Enrollment
30
Registered
2026-02-20
Start date
2020-12-01
Completion date
2022-08-01
Last updated
2026-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CVA (Cerebrovascular Accident), Stroke

Keywords

Robot Assisted Therapy, Upper Extremity Paresis

Brief summary

The purpose of this study is to compare the differences in treatment characteristics and patient and therapist satisfaction, between Robot Assisted Therapy (RAT) and Conventional Occupational Therapy (COT) single session in individuals post stroke.

Detailed description

Method and research procedure: The study will include 30 sub-acute post stroke patients, aged 18-85, with severe motor impairment in the upper limb and with normal-mild cognitive ability, hospitalized at the Loewenstein Rehabilitation Hospital. Each subject will receive two 30-min treatment sessions, one Conventional Occupational Therapy (COT) and one Robot Assisted Therapy (RAT). Before and during each session, the Visual Analogue Scale (VAS) for reporting the level of pain will be administered. The number of repetitions and compensations will be counted by observation. After each session, a subjective satisfaction questionnaire regarding the treatment will be administered.

Interventions

OTHERRobot Assisted Therapy (RAT)

Robot Assisted Therapy (RAT): 30-min treatment session of active- assisted movements of shoulder and elbow, using a robotic arm and a computer screen, provides different exercises according to the motor ability of the patient. The robot provides proximal upper limb training in a three-dimensional (3D) environment. The occupational therapist will be planning the treatment by determining the range of motion, the amount of help and support and the level of difficulty of the game. Conventional occupational therapy (COT): 30-min treatment session of active- assisted movements of the shoulder and elbow, using conventional facilities and devices. Treatment includes passive range of motion exercises and active- assistive exercises. The level of support and help will be determined by the occupational therapist.

Sponsors

linor kennet
Lead SponsorOTHER
Tel Aviv University
CollaboratorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

1. 18 to 85 year old following stroke (first-ever stroke). 2. Individuals in the sub-acute phase (up to three months) 3. Intact cognitive function (score \> 21 points on the Mini Mental State Examination) 4. Sever weakness of the affected upper limb (score 5-20 points on the FMA) 5. Understanding and reading Hebrew 6. Normal or corrected eyesight. 7. Subjects were at least in one session of RAT and one session of COT

Exclusion criteria

1. Neurological, cardio-vascular or orthopedic impairment, unrelated to the stroke, which restrict upper limb function. 2. High muscle tone (score \> 4 in Modified Ashworth Scale) 3. Apraxia (score \<68 in De Renzi Apraxia Test) 4. Severe Sensory impairment.

Design outcomes

Primary

MeasureTime frameDescription
Observation30 minThe number of repetitions and compensations will be counted by observation

Secondary

MeasureTime frameDescription
VAS1minThe Visual Analogue Scale (VAS) is a common scale for estimating pain level from one to ten.
Questionnaire5 minA subjective satisfaction questionnaire regarding the treatment will be administered.

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 21, 2026